Patients With Focal Segmental Glomerulosclerosis (FSGS) Achieved Low Proteinuria Targets Earlier and More Often With Sparsentan (SPAR) vs Irbesartan (IRB) in DUPLEX
15th International Podocyte Conference and 2025 ISGD Meeting
June 10 - 13, 2025
Germany
Population modelling depicts the mutational burden of NPHS2 (podocin) nephropathy and reveals an undiagnosed adult-onset genetic cohort
62nd European Renal Association (ERA) Congress 2025
June 6 - 7, 2025
Austria
From Podocyte to Patient
Exploring Clinical Trial Endpoints in FSGS: Spotlight on Proteinuria
Travere and National Kidney Foundation Collaboration
Patients in DUPLEX Achieved Partial or Complete Remission of Proteinuria Earlier and More Often With Sparsentan vs Irbesartan: Implications for Slowing Progression to Kidney Failure in Focal Segmental Glomerulosclerosis (FSGS)
American Nephrology Nurses Association (ANNA) National Symposium 2025
May 1 - 4, 2025
OR
The Humanistic Burden of Focal Segmental Glomerulosclerosis on Patients and Care‑Partners in the United States
Patient-Reported Outcomes in Rare Kidney Disease Clinical Trials: Sparsentan Versus Irbesartan
Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis
National Kidney Foundation (NKF) Spring Clinical Meetings 2025
April 10 - 13, 2025
Boston